Tonix Pharmaceuticals Holding Corp.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Tonix Pharmaceuticals Holding Corp.
New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.
Keeping Track: Good News For Deciphera, BMS And Clovis; Bad News For bluebird/BMS, Blueprint And Tonix
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Tonix Pharmaceuticals’ sublingual cyclobenzaprine has failed to show better efficacy than placebo in an interim analysis of the Phase III RECOVERY trial in post-traumatic stress disorder patients, although the study will continue to completion in already-enrolled patients. The product is also in development for fibromyalgia.
The New York biotech announces option deals with two universities, asset license from CBM BioPharma. Bayer inks research collaborations with Japan’s RiKen and with a pair of Boston research hospitals.
- Drug Delivery
- Large Molecule
- Other Names / Subsidiaries
- Krele Pharmaceuticals
- Tonix Pharmaceuticals Holding Corporation